Treatment of post-cholecystectomy biliary strictures with fully-covered self-expanding metal stents – results after 5 years of follow-up

Andrea Tringali 1,2*, D. Nageshwar Reddy 3, Thierry Ponchon 4, Horst Neuhaus 5, Ferrán González-Huix Lladó 6, Claudio Navarrete 7, Marco J. Bruno 8, Paul P. Kortan 9, Sundeep Lakhtakia 10, Matthew Rousseau 10, David Carr-Locke 11, Jacques Devière 12, Guido Costamagna 1,2 and for the Benign Biliary Stenoses Working Group

Abstract

Background: Endoscopic treatment of post-cholecystectomy biliary strictures (PCBS) with multiple plastic biliary stents placed sequentially is a minimally invasive alternative to surgery but requires multiple interventions. Temporary placement of a single fully-covered self-expanding metal stent (FCSEMS) may offer safe and effective treatment with fewer re-interventions. Long-term effectiveness of treatment with FCSEMS to obtain PCBS resolution has not yet been studied.

Methods: In this prospective multi-national study in patients with symptomatic benign biliary strictures (N = 187) due to various etiologies received a FCSEMS with scheduled removal at 6–12 months and were followed for 5 years. We report here long-term outcomes of the subgroup of patients with PCBS (N = 18). Kaplan Meier analyses assessed long-term freedom from re-stenting. Adverse events were documented.

Results: Endoscopic removal of the FCSEMS was achieved in 83.3% (15/18) of patients after median indwell of 10.9 (range 0.9–13.8) months. In the remaining 3 patients (16.7%), the FCSEMS spontaneously migrated and passed without complications. At the end of FCSEMS indwell, 72% (13/18) of patients had stricture resolution. At 5 years after FCSEMS removal, 84.6% (95% CI 65.0–100.0%) of patients who had stricture resolution at FCSEMS removal remained stent-free. In addition, at 75 months after FCSEMS placement, the probability of remaining stent-free was 61.1% (95% CI 38.6–83.6%) for all patients. Stent or removal related serious adverse events occurred in 38.9% (7/18) all resolved without sequelae.

Conclusions: In patients with symptomatic PCBS, temporary placement of a single FCSEMS intended for 10–12 months indwell is associated with long-term stricture resolution up to 5 years. Temporary placement of a single FCSEMS may be considered for patients with PCBS not involving the main hepatic confluence.

Trial registration numbers: NCT01014390; CTRI/2012/12/003166; Registered 17 November 2009.

Keywords: Benign biliary stricture, Cholecystectomy, V fully-covered self-expanding metal stents

* Correspondence: andrea.tringali@unicatt.it
1 Fondazione Polliclinico Universitario A. Gemelli IRCCS, Digestive Endoscopy Unit, Rome, Italy
2 Università Cattolica del Sacro Cuore, Centre for Endoscopic Research Therapeutics and Training (CERITI), Rome, Italy
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Endoscopic stenting is a recognized [1, 2] and increasingly adopted treatment modality for benign biliary strictures (BBS). Endotherapy of BBS may include any combination of ductal dilation with biliary balloons and extended duration endoscopic stenting. The latter involves placement of multiple plastic stents (MPS) and subsequent MPS exchanges every 3 to 4 months for approximately 1 year, or temporary placement of a fully covered self-expanding metal stent (FCSEMS). These endoscopic treatment modalities are all focused on re-establishing luminal patency.

Post-operative BBS most typically result from bile duct injury during cholecystectomy, with post-cholecystectomy biliary strictures (PCBS) occurring in 0–0.6% of laparoscopic cholecystectomy cases [3–5]. PCBSs may cause chronic cholestasis and jaundice, recurrent cholangitis, and secondary biliary cirrhosis, all of which can lead to serious and even fatal outcomes.

Endotherapy of post-operative BBS using a MPS technique was first reported in the late 1980s and 1990s using one or two biliary plastic stents [6–8]. The concept of using the MPS approach in a more aggressive manner until complete disappearance of the stricture was first reported in 2001 in a large series of 45 patients with BBS, of which 38 were PCBS [9]. Outcomes of endotherapy for these patients after mean follow-up of 13.7 years (range 11.7–19.8 years) was subsequently published in 2011 [10]. Results from endotherapy using MPS in PCBS were also reported from other studies [11–13]. The MPS therapeutic approach has high success rates, but requires multiple interventions and is technically demanding. Stricture dilation is step-wise in the MPS treatment approach. Increased number and/or diameter of plastic stents are inserted for about 3 months, then exchanged up to a cumulative stenting duration of approximately 1 year.

FCSEMSs, which are mounted on a delivery system with a diameter comparable to the diameter of one plastic stent, expand to a diameter similar to that of the largest bundle of MPS (seven 10 Fr plastic stents) after approximately 1 year of multi-procedure treatments (Fig. 1). However, use of FCSEMSs for endoscopic treatment of PCBS to date is considered investigational [1, 2]. This approach is gaining acceptance, but long-term follow-up is lacking. We previously reported the results of a prospective, non-randomized study assessing the placement of a biliary FCSEMS (WallFlex Biliary RX Stent; Boston Scientific, Natick, MA) with intended indwell for 6–12 months, in 187 patients with BBS secondary to chronic pancreatitis, or anastomotic BBS after orthotopic liver transplantation, or caused by bile duct injury during cholecystectomy (PCBS). Endoscopic removal of the FCSEMS was achieved in 83.3% (15/18) of patients with PCBS, after median indwell of 10.9 months (range 0.9–13.8 months); of these, a stent-in-stent removal technique was required in 1 patient without complications. In the remaining 3 patients (16.7%) with PCBS, the FCSEMS spontaneously migrated and passed without complications. Stricture resolution at the end of FCSEMS indwell was achieved in 72% (13/18) of patients. The present report provides long-term efficacy up to 5 years after FCSEMS removal in the subgroup of patients with PCBS.

Methods

Study design

The design of this study (NCT01014390 and CTRI/2012/12/003166) has been described previously [14]. The trial was approved by the Ethics Committee at each participating center and all patients provided written informed consent.

Adverse events were reported by the investigators and categorized as related or unrelated to the study stent, the stenting procedure, or the stent removal procedure. An independent medical reviewer (DCL) adjudicated the reported relatedness for all deaths and serious adverse events (SAEs). This independent review was carried out blinded to the study site.

Patients

Eligibility for the index FCSEMS placement procedure included patients ≥18 years old who underwent cholecystectomy and who were indicated to have endoscopic retrograde cholangiopancreatography (ERCP) and stent placement for treatment of BBS. Indications for ERCP were one or more of a symptomatic bile duct stricture, obstructive jaundice, persistent cholestasis and acute cholangitis. The FCSEMS was placed either in exchange of previously placed plastic stent(s),
or as initial treatment of a de novo biliary stricture as confirmed by ERCP.

Principal exclusion criteria were history of hepatectomy or liver transplantation, strictures within 2 cm of the hilum, prior biliary SEMS, bile duct perforation or fistula, suspected bile duct ischemia, symptomatic duodenal stenosis, biliary stricture of malignant etiology or benign etiology other than cholecystectomy-related bile duct injury, and strictures too tight to be dilated sufficiently to pass the stent delivery system.

Stenting and stent removal
The Fully-Covered WallFlex Biliary RX Stent is cleared in most countries outside of the United States for palliation of biliary obstructive symptoms caused by malignant biliary strictures and for treatment of BBS. In the United States it is cleared for palliation of malignant biliary strictures, but the BBS treatment clearance is restricted to BBS secondary to chronic pancreatitis.

The stent is available in 5 sizes, 8 × 60 mm, 8 × 80 mm, 10 × 40 mm, 10 × 60 mm, and 10 × 80 mm. It is made of radiopaque Nitinol wire and a silicone covering. Both ends are flared. The delivery system is 8.5F. It is customary to deploy the stent over an 0.035 in. wire under fluoroscopic guidance (Fig. 2).

The planned FCSEMS indwell duration was 10–12 months, which is a stenting duration similar to what is typical in the MPS treatment. The distal (duodenal) end of the stent has a retrieval loop to facilitate stent removal. Most often, the stent is removed with rat tooth forceps grasping the retrieval loop or by placing a snare over the distal end of the stent.

Assessments
The goal of PCBS treatment by temporary placement of a FCSEMS is for patients to remain stent-free for an extended period of time without interventions. The fraction of stent-free patients 5 years after FCSEMS indwell and reintervention rates were analyzed.

As previously reported [14] other key assessments were stricture resolution at the end of FCSEMS indwell, stricture recurrence, and adverse events. Stricture resolution was defined as the absence of a biliary stricture requiring restenting at the end of FCSEMS indwell. Stricture recurrence was defined as the need for restenting after stricture resolution, namely recurrence of a previously resolved stricture. Patients were followed until they underwent restenting or until they were stent-free for 5 years, whichever came first. For patients who failed the stent-free status earlier than 5 years after the end of FCSEMS indwell, further treatments were documented in an ad-hoc fashion.

Biliary obstructive symptoms, adverse events, and reinterventions were assessed at 1 week; at 1, 3, 6, and 9

![Fig. 2](image-url) a Cholangiogram showing a post cholecystectomy stricture at > 2 cm from the main hepatic confluence near the laparoscopic clips (arrow). b Fully Covered Wallflex stent is deployed. c Stricture resolution (arrow) after Wallflex removal.
months after FCSEMS placement; at FCSEMS removal; and at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months after FCSEMS removal. Proximal (towards the hilum) or partial distal (in the direction of the duodenum) migration of FCSEMS was assessed by ERCP.

ERCP was performed before and after FCSEMS placement, at FCSEMS removal, and at the time of reported recurrence of biliary obstructive symptoms.

**Statistical methods**
Summary statistics were performed to analyze the data for the study, specifically for continuous measurements, mean and standard deviation or median and range was reported and a Wilcoxon rank sum test was used to test between groups where appropriate. For binary data, the rate was reported and a 95% exact confidence interval (CI) was calculated where applicable. Stricture recurrence and freedom from restenting was analyzed using Kaplan-Meier techniques. Univariate and multivariate analyses were used for determining predictors of various endpoints. Specifically, logistic regression using a Firth bias adjustment was used for stricture resolution. For complications and stricture recurrence, a Cox proportional hazards model was performed. Both were performed using the model building technique of step-wise regression, with a $p$-value ≤ 0.10 to stay in the model and > 0.10 to exit the model. The significance level for all analyses was set at 0.05. All analyses were performed using SAS version 9.4.

**Results**

**Patients**
Eighteen patients were enrolled between December 2009 and May 2011 at 9 centers in Europe (6), India, Chile, and Canada. Mean age was 53.9 ±13.1 years and 33.3% (6/18) were male. The PCBS was located in the distal (4), mid (6) or proximal (8) bile duct. Most patients (77.8%, 14/18) had prior treatment of the PCBS with one or more plastic stents. All 18 patients completed the study (Table 1).

**Stent placement**
The majority of patients (89%, 16/18) received FCSEMS that were 10 mm in diameter. All FCSEMS were placed in trans-papillary position. Stent length was 40 mm (3), 60 mm (10), or 80 mm (5). One stent each were 8 mm × 60 mm and 8 mm × 80 mm in size.

**Shorter-term results**

**Stent removal or migration**
Endoscopic FCSEMS removal occurred in 83.3% (15/18) of patients after median indwell of 10.9 months (range 0.9–13.8 months). Early uneventful endoscopic FCSEMS removal was prompted by cholangitis in 4 patients after median indwell duration of 3.8 months (range 0.9–8.9 months).

In the remaining 3 patients (16.7%) with PCBS, the FCSEMS spontaneously migrated and passed without complications. One of these complete distal migrations (CDMs) was noted at the time of intended removal, 10.8 months. The other two were found at 5.1 and 6.3 months, one suffered from cholangitis and the other had a recurrent stricture. However, in each of these 3 patients the true indwell duration of the FCSEMS is not known.

**Stricture resolution**
At the end of FCSEMS indwell, 72% (13/18) of patients had stricture resolution. Of these, 10 patients had FCSEMS indwell duration as planned, 2 underwent early FCSEMS removal due to cholangitis after 59 and 174 days, and 1 had asymptomatic CDM. These 13 patients were considered at risk for stricture recurrence during subsequent follow-up. (Fig. 3).

Excluding the 3 patients with CDM after unknown indwell duration, median FCSEMS indwell duration was 11.3 (range 1.9–13.8) months for the 12 patients with stricture resolution at endoscopic FCSEMS removal vs. 8.9 (range

![Table 1 Baseline characteristics of patients with post-cholecystectomy biliary strictures](https://example.com/table1.png)
0.9–10.8) months for the 3 patients without stricture resolution at endoscopic FCSEMS removal ($P = 0.12$). Stricture resolution occurred in 90.9% (10/11) of patients after indwell duration as planned vs. 50% (2/4) after early FCSEMS removal due to cholangitis ($P = 0.15$).

In a univariate analysis of predictors (including age, sex, proximal stricture location, prior plastic stenting, procedure time, and stent length) for stricture resolution at FCSEMS removal, no significant predictors were found (Fig. 4).

### Longer-term outcomes

#### Stricture recurrence

At 60 months of follow-up, of the 13 patients with stricture resolution at FCSEMS removal or CDM, 2 experienced stricture recurrence, one associated with cholangitis after 2.6 months and one with biliary obstruction after 13.1 months.

In a univariate analysis of predictors (including age, sex, proximal stricture location, prior plastic stenting, procedure time, and stent length) for stricture recurrence at FCSEMS removal, no significant predictors were found (Fig. 5).

#### Freedom from Restenting

In Kaplan-Meier analysis, at 5 years after FCSEMS removal, the probability of remaining stent-free was 84.6% (95% CI 65.0–100.0%) for patients who had stricture resolution at FCSEMS removal (Fig. 6).

In Kaplan-Meier analysis, at 75 months after FCSEMS placement, the probability of remaining stent-free was 61.1% (95% CI 38.6–83.6%) for all patients who had FCSEMS placement for treatment of PCBS (Fig. 7).

#### Treatment after stent dysfunction

Throughout the entire course of the study, 7 patients were restented due to loss of stent functionality or recurrence of stricture. Two developed cholangitis leading to early stent removal; 2 had symptoms of biliary obstruction associated with CDM; 1 had unresolved stricture at the time of planned FCSEMS removal; and 2 had recurrence of the stricture after a stent-free period.

All 7 of these patients were restented with plastic biliary stents. Subsequent to plastic restenting, 5 patients underwent 1–3 additional plastic stenting procedures and ultimately were stent-free with normal liver function tests at 5–7 years follow-up after restenting; 1 patient

### Table 2

| Endoscopic FCSEMS Removal | PCBS | 95% CI |
|---------------------------|------|--------|
| N=18                      |      |        |
| Planned, at 10–12 months  | 83.3% (15/18) | 58.6–96.4% |
| Early, prior to 10–12 months | 61.1% (11/18) | 35.8–82.7% |
| Spontaneous CDM           | 22.2% (4/18) | 6.4–47.6% |
| Stricture Resolution at End of FCSEMS Indwell | 16.7% (3/18) | 3.9–41.4% |
| Overall Adverse Event Rate | 72.2% (13/18) | 46.5–90.3% |
|                           | 38.9% (7/18) | 17.3–64.3% |

**Abbreviations**: CDM complete distal migration, CI confidence interval, FCSEMS fully-covered, self-expanding metal stent, PCBS post-cholecystectomy biliary stricture

---

**Fig. 3** Patient flowchart. The flowchart shows occurrence of post-cholecystectomy biliary strictures resolution after FCSEMS removal and the stricture recurrence at 5 years follow-up in the 13 cases with initial stricture resolution.
underwent a surgical biliary-enteric anastomosis; and 1 patient was lost to follow-up.

**Adverse events**

Stent-related or procedure-related SAEs occurred in 38.9% (7/18) (95% CI 17.3–64.3%) of patients, including cholangitis (6) and pancreatitis (1), and are detailed as follows. Four patients experienced cholangitis that led to early removal of the FCSEMS, 2 of which were immediately restented with plastic stents and 2 remained stent-free for 5 years. One patient developed cholangitis associated with spontaneous CDM of the FCSEMS and was restented with plastic stents. One patient presented with cholangitis at 9.7 months after FCSEMS placement followed by FCSEMS removal as planned after 10.8 months of indwell, without stricture resolution; the patient

![Fig. 4 Independent variables by post-cholecystectomy biliary strictures resolution at FCSEMS removal. Univariate Forest Plot of Stricture Resolution at Removal](image)

![Fig. 5 Independent variables by post-cholecystectomy biliary strictures recurrence after initial resolution at FCSEMS removal. Univariate Forest Plot of Stricture Recurrence after Resolution](image)
was restented with plastic stents. One patient experienced mild post-ERCP pancreatitis after FCSEMS removal as planned, which resolved 6 days post-FCSEMS removal without residual effects; the patient remained stent-free for 2.9 months. All SAEs resolved without sequelae.

**Discussion**

In this small, prospective, nonrandomized study, 13 of 18 patients with PCBS experienced stricture resolution upon FCSEMS removal or CDM, and at 5 years follow-up, 84.6% (95% CI 65.0–100.0%) of these patients with PCBS remained stent-free.
initial resolution remained stent-free. In Kaplan-Meier analysis, at 75 months after FCSEMS placement, the probability of remaining stent-free was 61.1% (95% CI 38.6–83.6%) for all patients who received an FCSEMS for treatment of PCBS. The overall adverse event rate was 38.9% (95% CI 17.3–64.3%). These results suggest safe and effective treatment of symptomatic PCBS not involving the main hepatic confluence.

Endoscopic removal took place as planned after 10–12 month indwell in 11 patients, early due to cholangitis in 4 patients, and 3 had CDM. Although there was no significant difference in stricture resolution between the groups (90.9% with indwell duration as planned vs. 50% after early removal, $P=0.15$), the small sample size may have limited the ability to detect a difference in whether the duration of stenting affects stricture resolution (Table 3).

In 1 patient, the FCSEMS was difficult to remove due to the proximal end being embedded in hyperplastic tissue at the level of cholecystectomy clips; the attempted stent removal was stopped and a new FCSEMS was placed inside of the study stent. Both FCSEMSs were removed endoscopically and uneventfully 2 weeks later according to the “stent-in-stent technique” [15]. This patient remained stent-free for 2.5 months, and then had early stricture recurrence maybe related to the development of hyperplasia and subsequent trauma due to difficult FCSEMS retrieval. The rate of cholangitis in our series was high (6/18) but were successfully resolved by medical/endoscopic treatment without any impact on stricture resolution.

Larger series described the use of FCSEMS to dilate BBS, but looking into subgroup analysis these studies included fewer cases of PCBS, compared to our experience [16–19]. Our study also provided longer follow-up than most other published reports. Nonetheless, relatively promising results were demonstrated pertaining to stricture patency [20, 21]. In addition to maintaining bile duct patency and preventing stricture recurrence, endoscopic therapy of BBS reduced morbidity and mortality, as compared with surgical therapy [22]. Typical endotherapy with MPS includes stent exchanges every 3–4 months, resulting in at least 3 procedures per year. In the present study, 11 patients had their FCSEMS removed at the planned timeframe of 10–12 months. When compared with multiple exchanges of plastic stents over the course of 1 year, this indicates that these 11 patients had approximately 2 fewer endoscopic procedures than they would have if treated with plastic stents. FCSEMS can bring the advantage of fewer ERCPs leading to better patient compliance with reduced burdensome endoscopic treatments. Moreover, maximal dilation is reached rapidly after FCSEMS placement compared to a progressive step-wise dilation when inserting MPS in increasing numbers in successive plastic stenting episodes. The potential associated post-FCSEMS placement pain was not observed in the present study. It should also be noted that reaching the same maximal dilation with MPS compared to an 8 mm or 10 mm diameter FCSEMS is not always technically feasible. Accordingly, given the high rate of continued stricture resolution and freedom from restenting in the present study at 36, 48, and even 60 months (Fig. 6), treatment with FCSEMS should be considered a viable long-term therapy for patients with PCBS not involving the main hepatic confluence.

Three patients in the present study experienced CDM. Spontaneous migration may be a possible risk factor for failure of stricture resolution. Of these 3 patients, only 1 had stricture resolution [1, 2]. Antimigration mechanism for FCSEMS to avoid migration seem promising but need further evaluation [1, 2].

Seven patients were restented with plastic biliary stents and 5 underwent repeated ERCPs for stent exchanges. The possibility for endoscopic retreatment of PCBS recurrence represents the key advantage of endotherapy which can be repeated using the same access. One patient underwent a surgical biliary-enteric anastomosis meaning that endoscopy does not preclude future surgical options if needed.

The limitations of our study include a small sample size and the lack of a control group. Larger patient samples specific to PCBS with follow-up durations comparable to that evaluated in our study are expected. Additionally, it should be noted that treatment with FCSEMS is not a panacea for all PCBS and is limited to strictures located > 2 cm from the main hepatic confluence, due to the risk of side-branch occlusion [1, 2].

### Table 3 Results of endoscopic dilation of post-cholecystectomy biliary strictures with fully-covered self-expanding metal stent (FCSEMS) by removal type

|                          | Planned Removal | Early Removal | CDM |
|--------------------------|-----------------|---------------|-----|
| Number of patients (n)   | 11              | 4             | 3   |
| Median months of indwell time (range) | 11.5 (10.4–13.8) | 3.8 (0.9–8.9) | 6.2 (5.1–10.8) |
| Stricture Resolution at End of FCSEMS Indwell (n) | 10 | 2 | 1 |
| Stent free status at 5 years (n) | 8 | 2 | 1 |

*Abbreviations: CDM complete distal migration, CI confidence interval, FCSEMS fully-covered, self-expanding metal stent*
Conclusion
In conclusion, this prospective multi-center study indicates that treatment with FCSEMS is effective for maintaining long-term stricture resolution in patients with “non-hilar” PCBS. Randomized controlled trials are needed to better assess the role and the long-term efficacy of FCSEMS compared with MPS in the treatment of PCBS.

Abbreviations
BBS: Benign biliary strictures; CDMs: Complete distal migrations; CI: Confidence interval; ERCP: Endoscopic retrograde cholangiopancreatography; FCSEMS: Fully-covered self-expanding metal stent; MPS: Multiple plastic stents; PCBS: Post-cholecystectomy biliary strictures; SAEs: Serious adverse events

Acknowledgements
Joanna Suomi helped with the writing and editing of this manuscript, and was compensated by Boston Scientific for her work. Erin Leckrone lead the conduct of the study for Boston Scientific Corporation.

Authors’ contributions
AT, JP, and MR drafted the manuscript. All authors critically reviewed the manuscript, provided critical revision for important intellectual content and interpreted the data. MR analyzed the data. JP, MR, GC, and JD designed and coordinated the study. AT, GC, JD, DNR, TP, HN, FGH-L, CN, MJ, FPK, and SL screened and enrolled patients, performed study procedures, and conducted follow-up. DCL interpreted the data. All authors provided final approval of the submitted version. All authors were personally accountable for the author’s own contributions and ensured that questions related to the accuracy or integrity of any part of the work.

Funding
The trial was sponsored by Boston Scientific Corporation and the sponsor participated in the design, analysis of the data, and in writing the manuscript. All data was collected via a web-based database and the sponsor had no access to edit or edit any data.

Availability of data and materials
The data, analytic methods, and study materials for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy: http://www.bostonscientific.com/en-US/data-sharing-requests.html

Ethics approval and consent to participate
The trial was approved by all center’s IRBs or ethic committees and all patients provided written informed consent and gave approval to participate in the trial. The IRBs or ethic committees that were used are as follows: Comitato Etico Policlinico A. Gemelli – Università Cattolica del Sacro Cuore, Roma for Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. The Ethics Committee, Asian Institute of Gastroenterology for Asian Institute of Gastroenterology. The CPP SUD-EST III for Hôpital Edouard Herriot. The International Medical Ethics Commission for Medizinische Klinik, Evangelisches Krankenhaus Düsseldorf. The Comite Etico de Investigacion Clinica Del Hospital Universitario de Girona Doctor Josep Trueta for Hospital Universitari Doctor Josep Trueta. The Ethics Committee – Clinical Alemana de Santiago for Clinica Alemana de Santiago. The METC Erasmus MC for Erasmus Universitair Medisch Centrum. The Research Ethics Board, St. Michael’s Hospital for St. Michael’s Hospital. The Ethics Committee Erasmus Hospital for Universite Libre de Bruxelles Hôpital Erasme.

Consent for publication
N/A

Competing interests
Dr. Tringali has no conflicts of interest or financial ties to disclose. Dr. Reddy has no conflicts of interest or financial ties to disclose.

Dr. Ponchon reports grants from Boston Scientific, during the conduct of the study; personal fees from Olympus Company, personal fees from Boston Scientific, personal fees from Norgine, personal fees from Fujifilm, personal fees from Ipsen, outside the submitted work.

Dr. Neuhaus reports receiving honorarium for consulting and speaking for Boston Scientific.

Dr. González-Huix Lladó reports other from Boston Scientific, during the conduct of the study; other from null, outside the submitted work.

Dr. Navarrete reports reports grants from Boston Scientific Corporation, during the conduct of the study.

Dr. Bruno reports grants from Boston Scientific, grants from Cook Medical, grants from 3 M, grants from Pentax Medical, personal fees from Boston Scientific, personal fees from Cook Medical, personal fees from 3 M, personal fees from Pentax Medical, personal fees from Mylan, personal fees from SOCAR, outside the submitted work.

Dr. Kortan reports grants from Boston Scientific Corporation, during the conduct of the study.

Dr. Lahlhtakia has no conflicts of interest or financial ties to disclose.

Dr. Peetermans is an employee of Boston Scientific Corporation, the sponsor of this study.

Dr. Carr-Locke reports other from Steris Corporation, other from Telmed Systems, other from Boston Scientific Corporation, outside the submitted work.

Dr. Devière reports receiving Research support for IRB approved studies; Boston Scientific, Cook medical, Olympus, Fractyl, and Endotools, outside the submitted work.

Mr. Rousseau is an employee of Boston Scientific Corporation, the sponsor of the study.

Dr. Costamagna reports grants from Cook Endoscopy, grants from Olympus, grants from Boston Scientific, grants from Tae Woong, during the conduct of the study.

Author details
1Fondazione Policlinico Universitario A. Gemelli IRCCS, Digestive Endoscopy Unit, Rome, Italy. 2Università Cattolica del Sacro Cuore, Centre for Endoscopic Research Therapeutics and Training (CERTTI), Rome, Italy. 3Gastroenterology and Therapeutic Endoscopy, Asian Institute of Gastroenterology, Hyderabad, India. 4Service de Gastroentérologie et d’Endoscopie Digestive, Hôpital Edouard Herriot, Lyon, France. 5Medizinische Klinik, Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany. 6Unidad de Endoscopia, Servicio de Aparato Digestivo, Hospital Universitari Doctor Joseph Trueta, Girona, Catalunya, Spain. 7Servicio de Endoscopia, Clínica Alemana de Santiago. Jefe de Departamento de Cirugía, Clínica Santa María, Santiago, Chile. 8Maag-, Darm- en Leverziekten, Erasmus Universitair Medisch Centrum, Rotterdam, The Netherlands. 9Division of Gastroenterology, Centre for Therapeutic Endoscopy and Endoscopic Oncology, St. Michael’s Hospital, Toronto, Ontario, Canada. 10Boston Scientific Corporation, Marlboro, Massachusetts, United States. 11The Center for Advanced Digestive Care, Weill Cornell Medicine, New York Presbyterian Hospital, New York, USA. 12Gastro-Entérologie et d’Hépatogastro-Pancréatologie, Université Libre de Bruxelles Hôpital Erasme, Brussels, Belgium.

Received: 22 March 2019 Accepted: 22 November 2019

Published online: 12 December 2019

References
1. Chandrasekhara V, Chathadi KV, Acosta RD, Decker GA, Early DS, Eloubeidi MA, Evans JA, Falk AL, Fanelli RD, Fisher DA, Foley K, Forsntaksov L, Hwang JH, Jue TL, Khathab MA, Lighthard JR, Mathusamy VR, Pasha SF, Saltzman JR, Sharaf R, Shaukat A, Shergill AK, Wang A, Cash BD, DeWitt JM, Committee, A. S. o. P. The role of endoscopy in benign pancreatic disease. Gastrointest Endosc. 2013;82(2):203–14.

2. Dumonceau JM, Tringali A, Papanikolaou IS, Biero D, Mangiavilliano B, Schmidt A, Vanbiervliet G, Costamagna G, Deviere J, Garcia-Jiménez J, Gyökeres T, Hassan C, Prat F, Siersens RD, van Hooft JE. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline - updated October 2017. Endoscopy. 2018;50(9):910–30.

3. Fullum TM, Downing SR, Ortega G, Chang DC, Oyetunji TA, Van Kirk K, Tran DD, Woods I, Cornell EE, Turner PL. Is laparoscopy a risk factor for bile duct injury during cholecystectomy? JSLS. 2013;17(3):365–70.
4. Fortunato AA, Gentile JK, Caetano DP, Gomes MA, Bassi MA. Comparative analysis of iatrogenic injury of biliary tract in laparotomic and laparoscopic cholecystectomy. Arq Bras Cir Dig. 2014;27(4):272–4.

5. Pekolj J, Alvarez FA, Palavecino M, Sánchez Clarán R, Mazza G, de Santibañes E. Intraoperative management and repair of bile duct injuries sustained during 10,123 laparoscopic cholecystectomies in a high-volume referral center. J Am Coll Surg. 2013;216(5):894–901.

6. Geenen DJ, Geenen JE, Hogan WJ, Schenck J, Venu RP, Johnson GK, Jackson A. Endoscopic therapy for benign bile duct strictures. Gastrointest Endosc. 1989;35(5):367–71.

7. Williams HJ, Bender CE, May GR. Benign postoperative biliary strictures: dilation with fluoroscopic guidance. Radiology. 1987;163(3):629–34.

8. Lillemoe KD, Pitt HA, Cameron JL. Endoscopic therapy for benign bile duct strictures. Surg Clin North Am. 1990;70(6):1355–80.

9. Costamagna G, Pandolfi M, Mutignani M, Spada C, Perri V. Long-term results of endoscopic management of postoperative bile duct strictures with increasing numbers of stents. Gastrointest Endosc. 2001;54(2):162–8.

10. Costamagna G, Tringali A, Mutignani M, Perri V, Spada C, Pandolfi M, Galasso D. Endotherapy of postoperative biliary strictures with multiple stents: results after more than 10 years of follow-up. Gastrointest Endosc. 2010;72(3):551–7.

11. Canena J, Liberato M, Coutinho AP, Marques I, Romanò C, Veiga PM, Neves BC. Predictive value of cholangioscopy after endoscopic management of early postcholecystectomy bile duct strictures with an increasing number of plastic stents: a prospective study (with videos). Gastrointest Endosc. 2014;79(2):279–88.

12. Baron TH, Davee T. Endoscopic management of benign bile duct strictures. Gastrointest Endosc Clin N Am. 2013;23(2):295–311.

13. Kuzela L, Olmstar M, Sukta J, Hricka R, Novotna T, Vavrecka A. Prospective follow-up of patients with bile duct strictures secondary to laparoscopic cholecystectomy, treated endoscopically with multiple stents. Hepatogastroenterology. 2005;52(65):1357–61.

14. Devière J, Nageshwar Reddy D, Puspok A, Ponchon T, Bruno MJ, Bourke MJ, Neuhau H, Roy A, González-Huix Ládf, Barkun AN, Kortan PP, Navarete C, Peetemans J, Blero D, Lakhtakia S, Dolak W, Lepilliez V, Poley JW, Tringali A, Costamagna G, Group, B. B. S. W. Successful management of benign biliary strictures with fully covered self-expanding metal stents. Gastroenterology. 2014;147(2):385–95 quiz e15.

15. Tringali A, Blero D, Bolškovski I, Familiari P, Perri V, Devière J, Costamagna G. Difficult removal of fully covered self expandable metal stents (SEMS) for benign bile duct strictures: the “SEMS in SEMS” technique. Dig Liver Dis. 2014;46(6):568–71.

16. Kahele MH, Brijbassie A, Sethi A, Degaetani M, Pooner JM, Loren DE, Kowalski TE, Sejpal DV, Patel S, Rosenkranz L, McNamara KN, Rajmain I, Taleja JP, Gaighane M, Sauer BG, Stevens PD. Multicenter trial evaluating the use of covered self-expanding metal stents in benign bile duct strictures time to revisit our therapeutic options? J Clin Gastroenterol. 2013;47(8):695–9.

17. Irani S, Baron TH, Ahkbar A, Lin OS, Gluck M, Gan I, Ross AS, Petersen BT, Topazian M, Kozarek RA. Endoscopic treatment of benign bile duct strictures using covered self-expanding metal stents (CSEMS). Dig Dis Sci. 2014;59(11):1542–8.

18. Saxena P, Diehl DL, Kumbhari V, Shieh F, Buscaglia JW, Sez W, Kapoor S, Komanduri N, Naar J, Shin EJ, Singh V, Lennon AM, Kalloo AN, Khoshaba MA. A US multicenter study of safety and efficacy of fully covered self-expanding metallic stents in benign extrahepatic biliary strictures. Dig Dis Sci. 2015;60(11):3442–8.

19. Chaput U, Vienne A, Audureau E, Bauret P, Richard P, Coumaros D, Napoleon B, Ponchon T, Buchmann JC, Laugier R, Lamouliatte H, Vedrenne B, Gaudin C, Chausse E, Robin F, Leblanc S, Prat F. Temporary placement of fully covered self-expanding metal stents for treatment of benign bile duct strictures. United European Gastroenterol J. 2016;4(3):403–12.

20. Haseeb A, Siddiqui A, Taylor LS, Mills A, Kowalski TE, Loren DE, Dahmus J, Yalamanchili S, Cao C, Canakis A, Mumtaz T, Parikh M, Adler DG. Use of fully covered self expanding metal stents for benign biliary etiologies: a large multi-center experience. Minerva Gastroenterol Dietol. 2018;64(2):111-16.

21. Lalezari D, Singh I, Reicher S, Eysselein VE. Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks. World J Gastroenterol. 2013;19(7):332–9.

22. Pausawasdi N, Soontornmanokkul T, Rerkmitr R. Role of fully covered self-expandable metal stent for treatment of benign bile duct strictures and bile leaks. Korean J Radiol. 2012;13(Suppl 1):567–73.

Publisher's Note
 Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.